Actively Recruiting
Evaluation of Surlorian Compared to Placebo for Muscle Strength and Safety in Adults with Autosomal Dominant RYR1-Related Myopathy
Led by RyCarma Therapeutics, Inc. · Updated on 2026-10-22
28
Participants Needed
9
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying surlorian, a medicine for adults with autosomal dominant RYR1-related myopathy RYR1-RM, a genetic muscle condition. The trial aims to evaluate if surlorian improves muscle weakness and to assess its safety and tolerability. This is a Phase 2, double-blind, placebo-controlled study conducted at specialized medical centers. Participants will receive both surlorian and a placebo during two treatment periods in a randomized crossover design. In the first 8-week treatment period, participants get either surlorian 300 mg once daily or placebo, followed by a washout. Then they switch to the other treatment in the second 8-week period. After completing these 16 weeks, participants may join a 12-month open-label extension where all receive surlorian. Throughout the study, participants undergo assessments of muscle strength and physical function, including sit-to-stand tests and walking tests, at baseline and after treatment periods. Researchers monitor safety through vital signs, blood tests, and adverse event reporting up to about 68 weeks. The study tracks changes from baseline in various physical and laboratory measures to determine surlorians effects and safety over time.
CONDITIONS
Brief Title
A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
Research Team
P
Patrick Round
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here